

2025 ANNUAL REPORT BRIEF

PATIENT OUTCOMES

Ideal Option provides low-barrier treatment to people struggling with substance use disorder.


Ideal Option has been providing evidence-based treatment for substance use disorder using FDA-approved medications – the gold standard in addiction treatment – for more than six years.




6
Clinics




773
Patient Census
as of December 31, 2025



Treatment Works¹



Life Improves²




Retention



¹The reduction in positive tests for all patients during 2025 at Maintenance B compared to Initiation Stage of Care. ² Ideal Option Self-Reported Patient Outcomes Survey, November 2025, 876 Respondents.

Patient-Reported Data Show That Engagement in Treatment Leads to Significant Improvement in Quality of Life

Patient Challenges Before and After Starting Treatment




Have you visited the ER for drug-related medical care since starting treatment?
96% SAY NO



Have you had any drug-related arrests or charges since starting treatment?
98% SAY NO


Remission and Recovery Outcomes Improve With Each Stage of Care

Positive Opioid* Rates by Stage of Care



*Opioids include fentanyl, heroin, and prescription pain medication.

Positive Stimulant* Rates by Stage of Care



* Stimulants include methamphetamine and cocaine.

INITIATION

New patients, re-start patients, or patients not yet stabilized on buprenorphine.



STABILIZATION A

Patients who are starting to feel stable on buprenorphine and have reduced their use of opioids.



STABILIZATION B

Patients who are stable on buprenorphine and have stopped use of opioids but may still be using other non-prescribed substances.



MAINTENANCE A

Patients who are completely stable on buprenorphine and abstinent from all non-prescribed substances.



MAINTENANCE B

Patients who have long-term stability on buprenorphine and are abstinent from all non-prescribed substances.

